News & Updates

Show Multimedia Only

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025 by

The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025

Review underpins poor functional outcomes in AYAs with bony sarcomas

25 Jun 2025 by

In a scoping review examining the functional outcomes of individuals with bony sarcomas, adolescent and young adult oncology (AYAO) patients seem to fare worse than their healthy counterparts and bony sarcoma patients from various age groups.

Review underpins poor functional outcomes in AYAs with bony sarcomas

25 Jun 2025

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

24 Jun 2025 by

In the first interim analysis of the phase III KEYNOTE-689 trial, pembrolizumab improves event-free survival (EFS) and major pathological response (mPR) rate, independent of CPS*, when added to standard-of-care (SoC) treatment for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

24 Jun 2025

ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC

24 Jun 2025 by

Darolutamide demonstrated clinically meaningful delays in pain progression and deterioration of important patient-relevant health-related quality of life (HRQoL) outcomes vs placebo in men with metastatic hormone-sensitive prostate cancer (mHSPC), according to phase III ARANOTE trial findings presented at ASCO 2025. [ASCO 2025, abstract 5004]

ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC

24 Jun 2025

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

24 Jun 2025 by

A retrospective cohort study of >11,000 Hong Kong patients who initiated anthracycline-based chemotherapy found that both body-mass index (BMI) and glycaemic status significantly affect cardiovascular (CV) risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes.

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

24 Jun 2025

Long-term data solidify partial-breast RT as standard of care in low-risk early breast cancer

23 Jun 2025 by

In patients with low-risk, early-stage breast cancer who have undergone breast-conserving surgery, partial-breast radiotherapy (RT) is as safe and efficacious as whole-breast RT, according to 10-year data from the phase III IMPORT LOW trial.

Long-term data solidify partial-breast RT as standard of care in low-risk early breast cancer

23 Jun 2025

Penpulimab extends survival in R/M nasopharyngeal carcinoma

23 Jun 2025 by

The use of penpulimab, in combination with gemcitabine and cisplatin or carboplatin, as first-line treatment for recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) provides statistically significant and clinically meaningful benefit, according to a study presented at AACR 2025.

Penpulimab extends survival in R/M nasopharyngeal carcinoma

23 Jun 2025

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

20 Jun 2025

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic soft-tissue metastases that has progressed on an androgen receptor pathway inhibitor (ARPI), the combination of cabozantinib plus atezolizumab appears to prolong progression-free survival (PFS), according to data from the open-label phase 3 CONTACT-02 trial.

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

20 Jun 2025

Insulinemic lifestyle pattern ups risk of endometrial cancer

14 Jun 2025

A lifestyle pattern with higher insulinemic potential may predispose an individual to endometrial cancer (EC), suggests a study.

Insulinemic lifestyle pattern ups risk of endometrial cancer

14 Jun 2025

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

14 Jun 2025

Treatment with the combination of zanidatamab plus palbociclib and fulvestrant is safe and demonstrates promising antitumour activity in patients with HR-positive, HER2-positive advanced or metastatic breast cancer, according to a phase IIa study.

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

14 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Diabetes in CHD patients ups risk of hepatocellular carcinoma

Diabetes in CHD patients ups risk of hepatocellular carcinoma

Review underpins poor functional outcomes in AYAs with bony sarcomas

Review underpins poor functional outcomes in AYAs with bony sarcomas

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC

ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

Long-term data solidify partial-breast RT as standard of care in low-risk early breast cancer

Long-term data solidify partial-breast RT as standard of care in low-risk early breast cancer

Penpulimab extends survival in R/M nasopharyngeal carcinoma

Penpulimab extends survival in R/M nasopharyngeal carcinoma

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

Insulinemic lifestyle pattern ups risk of endometrial cancer

Insulinemic lifestyle pattern ups risk of endometrial cancer

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer